New CIHR Clinical Trials Fund invests in 10 CCCTG-endorsed trials
Ten CCCTG-endorsed trials have been awarded more than $27M in funding from the Canadian Institutes of Health Research (CIHR) Spring 2022 Clinical Trials Fund. We celebrate the outstanding Canadian and international collaborations represented in these awards.
Congratulations to each of the teams on their success!
REVISE Renewal Grant Stress Ulcer Prophylaxis in the Critically Ill; (Deborah Cook, McMaster University) $1,863,000
BALANCE+: A Platform Trial for Gram Negative Bloodstream Infections (Nick Daneman, Sunnybrook Research Institute) $2,919,785
DRIVE RCT Driving Pressure-Limited Ventilation in Hypoxemic Respiratory Failure (Ewan Goligher, University Health Network)$7,078,340
ABOVE Trial: Advancing Brain Outcomes in pediatric critically ill patients sedated with Volatile AnEsthestic Agents: A pilot multicentre randomized controlled trial (Angela Jerath, Sunnybrook Research Institute) $1,121,996
inDEX trial: Non-invasive ventilation and dexmedetomidine in critically ill adults: An international pragmatic randomized controlled trial (Kim Lewis, McMaster University) $3,658,613
REMAP-CAP: The Randomized Embedded Multifactorial Adaptive Platform Trial in Community-Acquired Pneumonia: Enshrining a Global Pandemic Research Response to COVID-19 and Beyond (John C. Marshall, Unity Health Toronto) $3,532,110
REMAP-CAP: Randomized Embedded Multifactorial Adaptive Platform Trial of Community Acquired Pneumonia (Srinivas Murthy, University of British Columbia) $2,588,010
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock: A Phase II RCT (Lauralyn McIntyre, Ottawa Hospital Research Institute) $1,318,714
CORT-E2: The Corticosteroid Early and Extended Randomized Controlled Trial (Bram Rochwerg, McMaster University) $3,412,833
CAVIARDS: Careful Ventilation in Acute Respiratory Distress Syndrome (Laurent Brochard, Unity Health Toronto)$841,846
About the CIHR Clinical Trials Fund: Announced in Spring 2022, the Clinical Trials Fund earmarked $250M across three funding streams to grow and strengthen Canada’s clinical trials infrastructure, training, and research through 2025. It is an integral component of Canada's $2.2 billion investment under the Biomanufacturing and Life Sciences Strategy, which brings together a suite of federal programming to achieve two main objectives: (1) better preparing Canada to respond to pandemics and other health emergencies; and (2) supporting an innovative, high growth domestic life sciences sector.